scholarly journals MP08-17 BUDGET IMPACT ANALYSIS TO SUPPORT THE DECISION BETWEEN REPLACING REUSABLE FLEXIBLE URETEROSCOPES BY SINGLE USE DEVICES AND ADOPTING A HYBRID STRATEGY FOR THE UROLITHIASIS TREATMENT

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Benjamin Pradere ◽  
Dubnitskiy-Robin Sophie ◽  
benjamin Faivre D'Arcier ◽  
Sophie Watt ◽  
Tanguy Le Fol ◽  
...  
2021 ◽  
Vol 10 (12) ◽  
pp. 2593
Author(s):  
Fanny Monmousseau ◽  
Julien Ramillon ◽  
Sophie Dubnitskiy-Robin ◽  
Benjamin Faivre d’Arcier ◽  
Martine Le Verger ◽  
...  

Endoscopic procedures such as ureteroscopy (URS) have seen a recent increase in single-use devices. Despite all the advantages provided by disposable ureteroscopes (sURSs), their cost effectiveness remains questionable, leading most teams to use a hybrid strategy combining reusable (rURS) and disposable devices. Our study aimed to create an economic model that estimated the cut-off value of rURS procedures needed to support the profitability of a hybrid strategy (HS) for ureteroscopy. We used a budget impact analysis (BIA) model that estimated the financial impact of an HS compared to 100% sURS use. The model included hospital volume, sterilization costs and the private or public status of the institution. Although the hybrid strategy generally remains the best economic and clinical option, a predictive BIA model is recommended for the decision-making. We found that the minimal optimal proportion of rURS procedures in an HS was mainly impacted by the activity volume and overall number of sterilization procedures. Private and public institutions must consider these variables and models in order to adapt their HS and remain profitable.


2020 ◽  
Vol 23 ◽  
pp. S568
Author(s):  
W. Padula ◽  
S. Malaviya ◽  
N. Reid ◽  
F. Chingcuanco ◽  
J. Ballreich ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1612.2-1613
Author(s):  
J. M. Bello-Gualtero ◽  
O. J. Calixto ◽  
G. Salguedo ◽  
Y. M. Chamorro-Melo ◽  
C. A. Camargo Rodríguez ◽  
...  

Background:Spondyloarthritis refers to a family of diseases, of which ankylosing spondylitis and non-radiographic axial spondyloarthritis are responsible for axial impairment. Previously, the only treatment available were NSAIDs, which control activity and stop radiological progression, but at the expense of increased adverse effects, such as cardiovascular risk, dyspepsia and chronic renal failure. For the past 2 decades, biological therapy has been available, which means an increase in care costs.Objectives:The objective of this study is to perform a budget impact analysis of biologic therapy.Methods:To do a budget impact analysis from the perspective of the payer, comparing biological therapy with coventional therapy for the treatment of spondyloarthritis. Demographic characterization of the population attended at the Central Military Hospital. Time horizon from 2012 to 2018, taking the activity count according to the hospital’s billing and the prices of the activities of the state body SISMED. Exchange rates at the end of 2018.Results:The patients attended were 117, mostly men (63, 25%), average age 46, 4 years (SD 13), with disease diagnosis time of 9, 8 years (SD 9, 6). In the budget impact analysis, it is observed that 25% of patients were on DMARDs therapy, 22% with NSAIDs and 96% with biologic therapy. The average year/patient cost with NSAIDs alone would be EUR 381, with DMARDs only EUR 9,318 and, if only biological therapy was used, EUR 423. Within the total number of patients, the average annual cost, including the possibility of combining these drugs, amounted to EUR 5,403Conclusion:Including biological therapy in the care of patients with spondyloarthritis can increase up to 24 times the annual cost per patient. This increase is not only due to higher market value, it also relates to the need for more medical procedures and diagnostic follow-up tests.References:[1]Strömbeck, et al. Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care. J Rheumatol 2010;37;2348-2355.Disclosure of Interests:None declared


2012 ◽  
Vol 16 (1) ◽  
pp. 96-107 ◽  
Author(s):  
Laure Benjamin ◽  
Valérie Buthion ◽  
Michaël Iskedjian ◽  
Bechara Farah ◽  
Catherine Rioufol ◽  
...  

2021 ◽  
Vol 24 ◽  
pp. S81
Author(s):  
O. Siskou ◽  
A. Koutsovasilis ◽  
J. Doupis ◽  
I. Karagkouni ◽  
O. Konstantakopoulou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document